Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease by Beatriz Orts, Beatriz Orts, Ana Gutierrez, Ana Gutierrez, Ana Gutierrez, Lucía Madero, Lucía Madero, Laura Sempere, Laura Sempere, Ruben Frances, Ruben Frances, Ruben Frances, Pedro Zapater, Pedro Zapater, Pedro Zapater, Pedro Zapater

Connect to this object online.

Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU by Mariam Aguas, Javier Del Hoyo, Raquel Vicente, Manuel Barreiro-de Acosta, Luigi Melcarne, Alejandro Hernandez-Camba, Lucía Madero, María Teresa Arroyo, Beatriz Sicilia, María Chaparro, María Dolores Martin-Arranz, Ramón Pajares, Francisco Mesonero, Miriam Mañosa, Pilar Martinez, Silvia Chacón, Joan Tosca, Sandra Marín, Luciano Sanroman, Marta Calvo, David Monfort, Empar Saiz, Yamile Zabana, Ivan Guerra, Pilar Varela, Virginia Baydal, Raquel Faubel, Pilar Corsino, Sol Porto-Silva, Eduard Brunet, Melodi González, Ana Gutiérrez, Pilar Nos

Connect to this object online.